Catalent, Inc. (CTLT) |
| 63.48 0 (0%) 12-17 16:00 |
| Open: | 63.49 |
| High: | 63.5 |
| Low: | 63.44 |
| Volume: | 13,674,041 |
| Market Cap: | 11,522(M) |
| PE Ratio: | -27.84 |
| Exchange: | New York Stock Exchange |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 87.47 |
| Resistance 1: | 86.12 |
| Pivot price: | 85.40 |
| Support 1: | 83.93 |
| Support 2: | 69.83 |
| 52w High: | 63.5 |
| 52w Low: | 42.11 |
Catalent, Inc., operating globally through its various subsidiaries, specializes in the development and production of comprehensive solutions for a wide array of products, including pharmaceutical drugs, protein-based biologics, advanced cell and gene therapies, and consumer health items. The company's operations are strategically divided into four key segments: Biologics; Softgel and Oral Technologies; Oral and Specialty Delivery; and Clinical Supply Services. The Softgel and Oral Technologies division focuses on the formulation, development, and manufacturing of soft capsules. These are utilized in a diverse range of client products, such as prescription medications, over-the-counter drugs, nutritional supplements, unit-dose cosmetics, and medicinal preparations for animal health. Within the Biologics segment, Catalent undertakes the creation of biologic cell lines, develops and manufactures both cell therapy and viral-based gene therapy, and handles the formulation and production of parenteral dose forms, including vials, prefilled syringes, and cartridges. This segment also provides essential analytical development and testing capabilities. The Oral and Specialty Delivery segment offers extensive formulation, development, and manufacturing expertise across various technologies. It provides integrated downstream solutions spanning clinical development and commercial supply. This segment also features a dedicated oral delivery solutions platform, encompassing preclinical screening, formulation, analytical development, and current good manufacturing practices (cGMP) services. Finally, the Clinical Supply Services segment delivers vital support for drug and biologic clinical trials. Its services include manufacturing, specialized packaging, secure storage, efficient distribution, and comprehensive inventory management. This segment also offers "FastChain," a demand-led clinical supply service. Catalent serves a broad client base, including pharmaceutical, biotechnology, and consumer health organizations, alongside companies in other healthcare sectors like animal health and medical devices, and even the cosmetics industry. The company was founded in 2007 and maintains its headquarters in Somerset, New Jersey.
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Mon, 06 Jul 2026
If You Invested $1,000 in Catalent Inc (CTLT) - Stock Titan
Mon, 06 Jul 2026
Catalent stock leans on its contract services base - Ad-hoc-news.de
Tue, 05 Nov 2024
Catalent, Inc. Reports First Quarter Fiscal 2025 Results - Business Wire
Sat, 07 Sep 2024
EDGAR Filing Documents for 0001596783-24-000087 - SEC.gov
Thu, 29 Aug 2024
Catalent, Inc. Reports Fourth Quarter and Fiscal 2024 Results - TradingView
Fri, 05 Apr 2024
Ares (ARES), Blue Owl Lead $4.8 Billion Private Debt for Catalent (CTLT) Deal - Bloomberg.com
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |